Georg Auburger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1127468/publications.pdf

Version: 2024-02-01

142	20,805	36303	11308
papers	citations	51 h-index	136 g-index

149	149	149	28239
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prodromal Spinocerebellar Ataxia Type 2 Subjects Have Quantifiable Gait and Postural Sway Deficits. Movement Disorders, 2021, 36, 471-480.	3.9	40
2	Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders. Molecular Psychiatry, 2021, 26, 1286-1298.	7.9	33
3	Body Mass Index Is Significantly Associated With Disease Severity in Spinocerebellar Ataxia Type 2 Patients. Movement Disorders, 2021, 36, 1372-1380.	3.9	5
4	Weight loss is correlated with disease severity in Spinocerebellar ataxia type 2: a cross-sectional cohort study. Nutritional Neuroscience, 2021, , 1-9.	3.1	0
5	Loss of Mitochondrial Protease CLPP Activates Type I IFN Responses through the Mitochondrial DNAâ€“cGASâ€“STING Signaling Axis. Journal of Immunology, 2021, 206, 1890-1900.	0.8	27
6	Welcoming articles on genotype-dependent clinical features and diagnostics. Neurogenetics, 2021, 22, 103-104.	1.4	0
7	Prodromal sensory neuropathy in Pink1^{â^'/â^'}SNCA^{A53T} double mutant Parkinson mice. Neuropathology and Applied Neurobiology, 2021, 47, 1060-1079.	3.2	8
8	Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression. Neurobiology of Disease, 2021, 152, 105289.	4.4	24
9	Increased presence of nuclear DNAJA3 and upregulation of cytosolic STAT1 and of nucleic acid sensors trigger innate immunity in the ClpP-null mouse. Neurogenetics, 2021, 22, 297-312.	1.4	9
10	Inactivity of Peptidase ClpP Causes Primary Accumulation of Mitochondrial Disaggregase ClpX with Its Interacting Nucleoid Proteins, and of mtDNA. Cells, 2021, 10, 3354.	4.1	4
11	Oneâ€‘carbon metabolism factor MTHFR variant is associated with saccade latency in Spinocerebellar Ataxia type 2. Journal of the Neurological Sciences, 2020, 409, 116586.	0.6	1
12	Systematic Surveys of Iron Homeostasis Mechanisms Reveal Ferritin Superfamily and Nucleotide Surveillance Regulation to be Modified by PINK1 Absence. Cells, 2020, 9, 2229.	4.1	9
13	High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease. Movement Disorders, 2020, 35, 1822-1833.	3.9	25
14	Mid-Gestation lethality of Atxn2l-Ablated Mice. International Journal of Molecular Sciences, 2020, 21, 5124.	4.1	13
15	Mouse Ataxin-2 Expansion Downregulates CamKII and Other Calcium Signaling Factors, Impairing Granuleâ€”Purkinje Neuron Synaptic Strength. International Journal of Molecular Sciences, 2020, 21, 6673.	4.1	13
16	Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease. Neurogenetics, 2020, 21, 187-203.	1.4	14
17	Generation of an Atxn2-CAG100 knock-in mouse reveals N-acetylaspartate production deficit due to early Nat8l dysregulation. Neurobiology of Disease, 2019, 132, 104559.	4.4	24
18	New alternative splicing variants of the ATXN2 transcript. Neurological Research and Practice, 2019, 1, 22.	2.0	13

#	Article	IF	Citations
19	Sensory neuropathy and nociception in rodent models of Parkinson's disease. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	22
20	SerThr-PhosphoProteome of Brain from Aged PINK1-KO+A53T-SNCA Mice Reveals pT1928-MAP1B and pS3781-ANK2 Deficits, as Hub between Autophagy and Synapse Changes. International Journal of Molecular Sciences, 2019, 20, 3284.	4.1	12
21	Global Proteome of LonP1+/â˜’ Mouse Embryonal Fibroblasts Reveals Impact on Respiratory Chain, but No Interdependence between Eral1 and Mitoribosomes. International Journal of Molecular Sciences, 2019, 20, 4523.	4.1	15
22	Sleep spindles and K-complex activities are decreased in spinocerebellar ataxia type 2: relationship to memory and motor performances. Sleep Medicine, 2019, 60, 188-196.	1.6	15
23	Ubiquitylome profiling of Parkin-null brain reveals dysregulation of calcium homeostasis factors ATP1A2, Hippocalcin and GNA11, reflected by altered firing of noradrenergic neurons. Neurobiology of Disease, 2019, 127, 114-130.	4.4	21
24	In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism. International Journal of Molecular Sciences, 2019, 20, 5854.	4.1	19
25	Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Annals of Clinical and Translational Neurology, 2018, 5, 128-137.	3.7	45
26	Progression of corticospinal tract dysfunction in pre-ataxic spinocerebellar ataxia type 2: A two-years follow-up TMS study. Clinical Neurophysiology, 2018, 129, 895-900.	1.5	16
27	Loss of mitochondrial protease ClpP protects mice from dietâ€induced obesity and insulin resistance. EMBO Reports, 2018, 19, .	4.5	75
28	LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1. Molecular Neurobiology, 2018, 55, 506-516.	4.0	27
29	The Andalusian Bipolar Family (ABiF) Study: Protocol and sample description. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2018, 11, 199-207.	0.3	0
30	Ataxia telangiectasia alters the ApoB and reelin pathway. Neurogenetics, 2018, 19, 237-255.	1.4	9
31	Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant Î±-Synuclein. International Journal of Molecular Sciences, 2018, 19, 1651.	4.1	19
32	Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway. Cerebellum, 2017, 16, 68-81.	2.5	49
33	Blood RNA biomarkers in prodromal PARK4 and REM sleep behavior disorder show role of complexin-1 loss for risk of Parkinson's disease. DMM Disease Models and Mechanisms, 2017, 10, 619-631.	2.4	20
34	Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature, 2017, 544, 367-371.	27.8	422
35	Quantitative Global Proteomics of Yeast PBP1 Deletion Mutants and Their Stress Responses Identifies Glucose Metabolism, Mitochondrial, and Stress Granule Changes. Journal of Proteome Research, 2017, 16, 504-515.	3.7	22
36	Early corticospinal tract damage in prodromal SCA2 revealed by EEG-EMG and EMG-EMG coherence. Clinical Neurophysiology, 2017, 128, 2493-2502.	1.5	29

#	Article	IF	Citations
37	Developing the field of neurogenetics. Neurogenetics, 2017, 18, 183-184.	1.4	0
38	Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2. Trends in Neurosciences, 2017, 40, 507-516.	8.6	51
39	Impact of Ataxin-2 knock out on circadian locomotor behavior and PER immunoreaction in the SCN of mice. Chronobiology International, 2017, 34, 129-137.	2.0	25
40	On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3. Brain Pathology, 2017, 27, 345-355.	4.1	36
41	Corticomuscular Coherence: a Novel Tool to Assess the Pyramidal Tract Dysfunction in Spinocerebellar Ataxia Type 2. Cerebellum, 2017, 16, 602-606.	2.5	21
42	Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation. Journal of Neuroinflammation, 2017, 14, 154.	7.2	63
43	PINK1 and Ataxin-2 as modifiers of growth. Oncotarget, 2017, 8, 32382-32383.	1.8	6
44	Methyl-Arginine Profile of Brain from Aged PINK1-KO+A53T-SNCA Mice Suggests Altered Mitochondrial Biogenesis. Parkinson's Disease, 2016, 2016, 1-13.	1.1	9
45	Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs. Frontiers in Cellular Neuroscience, 2016, 10, 226.	3.7	22
46	Spinocerebellar ataxia type 2: Measures of saccade changes improve power for clinical trials. Movement Disorders, 2016, 31, 570-578.	3.9	39
47	<scp>C</scp>entral motor conduction time as prodromal biomarker in spinocerebellar ataxia type 2. Movement Disorders, 2016, 31, 603-604.	3.9	18
48	Ataxin-2 (Atxn2)-Knock-Out Mice Show Branched Chain Amino Acids and Fatty Acids Pathway Alterations. Molecular and Cellular Proteomics, 2016, 15, 1728-1739.	3.8	70
49	Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels. Neurobiology of Disease, 2016, 96, 115-126.	4.4	29
50	Abnormal corticospinal tract function and motor cortex excitability in non-ataxic SCA2 mutation carriers: A TMS study. Clinical Neurophysiology, 2016, 127, 2713-2719.	1.5	27
51	Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1558-1569.	3.8	86
52	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
53	Age-Related Changes of 14-3-3 IsoformsÂinÂMidbrain of A53T-SNCA Overexpressing Mice. Journal of Parkinson's Disease, 2015, 5, 595-604.	2.8	5
54	Mutations in CIZ1 are not a major cause for dystonia in Germany. Movement Disorders, 2015, 30, 740-743.	3.9	12

#	Article	IF	Citations
55	The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies. Brain Pathology, 2015, 25, 121-135.	4.1	214
56	Both Ubiquitin Ligases FBXW8 and PARK2 Are Sequestrated into Insolubility by ATXN2 PolyQ Expansions, but Only FBXW8 Expression Is Dysregulated. PLoS ONE, 2015, 10, e0121089.	2.5	18
57	Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. Molecular Neurobiology, 2015, 52, 57-63.	4.0	20
58	PINK1 and Parkin Control Localized Translation of Respiratory Chain Component mRNAs on Mitochondria Outer Membrane. Cell Metabolism, 2015, 21, 95-108.	16.2	175
59	A Genetic Mouse Model of Parkinsonâ€™s Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine. Molecular Neurobiology, 2015, 52, 1152-1164.	4.0	16
60	Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. Human Molecular Genetics, 2015, 24, 1061-1076.	2.9	53
61	Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition. European Journal of Cell Biology, 2015, 94, 148-161.	3.6	29
62	Rodent Models of Autosomal Recessive Parkinson Disease. , 2015, , 329-343.		1
63	Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics, 2015, 16, 181-192.	1.4	51
64	No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. Brain, 2015, 138, 3316-3326.	7.6	54
65	12q24 locus association with type 1 diabetes:SH2B3orATXN2?. World Journal of Diabetes, 2014, 5, 316.	3.5	58
66	Mitochondrial Acetylation and Genetic Models of Parkinson's Disease. Progress in Molecular Biology and Translational Science, 2014, 127, 155-182.	1.7	19
67	Mutant Î±-Synuclein Enhances Firing Frequencies in Dopamine Substantia Nigra Neurons by Oxidative Impairment of A-Type Potassium Channels. Journal of Neuroscience, 2014, 34, 13586-13599.	3.6	113
68	Dysregulated expression of lipid storage and membrane dynamics factors in Tia1 knockout mouse nervous tissue. Neurogenetics, 2014, 15, 135-144.	1.4	47
69	The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics, 2014, 15, 189-192.	1.4	15
70	<scp>H</scp>untington's <scp>D</scp>isease (<scp>HD</scp>): Degeneration of Select Nuclei, Widespread Occurrence of Neuronal Nuclear and Axonal Inclusions in the Brainstem. Brain Pathology, 2014, 24, 247-260.	4.1	51
71	Loss of PINK1 Impairs Stress-Induced Autophagy and Cell Survival. PLoS ONE, 2014, 9, e95288.	2.5	39
72	Ataxin-2 Modulates the Levels of Grb2 and Src but Not Ras Signaling. Journal of Molecular Neuroscience, 2013, 51, 68-81.	2.3	41

#	Article	IF	Citations
73	Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Progress in Neurobiology, 2013, 104, 38-66.	5.7	283
74	Loss of mitochondrial peptidase Clpp leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Human Molecular Genetics, 2013, 22, 4871-4887.	2.9	151
75	Spinocerebellar ataxia type 2. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 103, 423-436.	1.8	63
76	ATXN2-CAG42 Sequesters PABPC1 into Insolubility and Induces FBXW8 in Cerebellum of Old Ataxic Knock-In Mice. PLoS Genetics, 2012, 8, e1002920.	3.5	68
77	Subthalamic Lesion or Levodopa Treatment Rescues Giant GABAergic Currents of PINK1-Deficient Striatum. Journal of Neuroscience, 2012, 32, 18047-18053.	3.6	16
78	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	3.2	94
79	Mechanisms underlying altered striatal synaptic plasticity in old A53T-Î± synuclein overexpressing mice. Neurobiology of Aging, 2012, 33, 1792-1799.	3.1	37
80	Primary Skin Fibroblasts as a Model of Parkinson's Disease. Molecular Neurobiology, 2012, 46, 20-27.	4.0	121
81	ATXN2 and Its Neighbouring Gene SH2B3 Are Associated with Increased ALS Risk in the Turkish Population. PLoS ONE, 2012, 7, e42956.	2.5	43
82	Mutations in CIZ1 cause adult onset primary cervical dystonia. Annals of Neurology, 2012, 71, 458-469.	5.3	128
83	The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiology of Disease, 2012, 45, 356-361.	4.4	66
84	A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. Journal of Neural Transmission, 2012, 119, 297-312.	2.8	30
85	Striatal Dopamine Transmission Is Subtly Modified in Human A53TÎ±-Synuclein Overexpressing Mice. PLoS ONE, 2012, 7, e36397.	2.5	25
86	Saccadic latency is prolonged in Spinocerebellar Ataxia type 2 and correlates with the frontal-executive dysfunctions. Journal of the Neurological Sciences, 2011, 306, 103-107.	0.6	26
87	Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cellular and Molecular Life Sciences, 2011, 68, 721-733.	5.4	73
88	Spinocerebellar Ataxia Type 2 (SCA2): Identification of Early Brain Degeneration in One Monozygous Twin in the Initial Disease Stage. Cerebellum, 2011, 10, 245-253.	2.5	26
89	Sleep Disorders in Spinocerebellar Ataxia Type 2 Patients. Neurodegenerative Diseases, 2011, 8, 447-454.	1.4	53
90	Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics, 2011, 20, 1697-1700.	2.9	127

#	Article	IF	Citations
91	Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19707-19712.	7.1	100
92	The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety, dementia and Parkinson's disease. Aging, 2011, 3, 5-9.	3.1	17
93	Solving a 50 year mystery of a missing OPA1 mutation: more insights from the first family diagnosed with autosomal dominant optic atrophy. Molecular Neurodegeneration, 2010, 5, 25.	10.8	15
94	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 2010, 466, 1069-1075.	27.8	1,117
95	Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nature Genetics, 2010, 42, 420-425.	21.4	262
96	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. PLoS ONE, 2010, 5, e11464.	2.5	119
97	Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. Journal of Cell Science, 2010, 123, 917-926.	2.0	212
98	Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration. PLoS ONE, 2009, 4, e5777.	2.5	305
99	Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis. Depression and Anxiety, 2009, 26, E111-E119.	4.1	1
100	The mitochondrial kinase PINK1, stress response and Parkinsonâ€™s disease. Journal of Bioenergetics and Biomembranes, 2009, 41, 481-486.	2.3	32
101	Ataxin-2 associates with rough endoplasmic reticulum. Experimental Neurology, 2009, 215, 110-118.	4.1	72
102	Spinocerebellar ataxia 2 (SCA2). Cerebellum, 2008, 7, 115-124.	2.5	182
103	Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cellular Signalling, 2008, 20, 1725-1739.	3.6	87
104	Parkinson patient fibroblasts show increased alpha-synuclein expression. Experimental Neurology, 2008, 212, 307-313.	4.1	78
105	Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Human Molecular Genetics, 2008, 17, 1465-1481.	2.9	107
106	Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neuroscience Letters, 2007, 414, 126-129.	2.1	26
107	The First Genomewide Interaction and Locus-Heterogeneity Linkage Scan in Bipolar Affective Disorder: Strong Evidence of Epistatic Effects between Loci on Chromosomes 2q and 6q. American Journal of Human Genetics, 2007, 81, 974-986.	6.2	49
108	Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin. Journal of Neuroscience, 2007, 27, 12413-12418.	3.6	466

#	Article	IF	Citations
109	Subthalamicâ€thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremorâ€"A unusual clinical benefit. Movement Disorders, 2007, 22, 732-735.	3.9	71
110	Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Research Reviews, 2007, 53, 235-249.	9.0	53
111	Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiology of Disease, 2007, 25, 401-411.	4.4	180
112	Prism adaptation in spinocerebellar ataxia type 2. Neuropsychologia, 2007, 45, 2692-2698.	1.6	39
113	Spinocerebellar Ataxia Type 3 (SCA3): Thalamic Neurodegeneration Occurs Independently from Thalamic Ataxin-3 Immunopositive Neuronal Intranuclear Inclusions. Brain Pathology, 2006, 16, 218-227.	4.1	61
114	Saccade Velocity as a Surrogate Disease Marker in Spinocerebellar Ataxia Type 2. Annals of the New York Academy of Sciences, 2005, 1039, 524-527.	3.8	20
115	Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Annals of Neurology, 2005, 57, 453-456.	5.3	105
116	Failure to Find Î±-Synuclein Gene Dosage Changes in 190 Patients With Familial Parkinson Disease. Archives of Neurology, 2005, 62, 96.	4.5	23
117	Genomewide Scan and Fine-Mapping Linkage Studies in Four European Samples with Bipolar Affective Disorder Suggest a New Susceptibility Locus on Chromosome 1p35-p36 and Provides Further Evidence of Loci on Chromosome 4q31 and 6q24. American Journal of Human Genetics, 2005, 77, 1102-1111.	6.2	56
118	Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiology of Aging, 2005, 26, 25-35.	3.1	82
119	Mutations in the Lysyl Oxidase Gene Not Associated with Intracranial Aneurysm in Central European Families. Cerebrovascular Diseases, 2004, 18, 189-193.	1.7	16
120	Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A. Neurogenetics, 2004, 5, 239-243.	1.4	45
121	Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Annals of Neurology, 2004, 56, 444-447.	5.3	88
122	Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1. Science, 2004, 304, 1158-1160.	12.6	3,060
123	Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Molecular and Cellular Neurosciences, 2003, 24, 419-429.	2.2	189
124	Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe. Stroke, 2003, 34, 1207-1211.	2.0	53
125	Saturating density of STSs (1/6â€‰kb) in a 1.1â€‰Mb region on 3q28-q29: a valuable resource for cloning of disease genes. European Journal of Human Genetics, 2001, 9, 307-310.	2.8	5
126	Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1. Nature Neuroscience, 2000, 3, 103-104.	14.8	1

#	Article	IF	Citations
127	OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nature Genetics, 2000, 26, 211-215.	21.4	1,169
128	Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathologica, 1999, 97, 306-310.	7.7	210
129	Identification of the Physiological Promoter for Spinocerebellar Ataxia 2 Gene Reveals a CpG Island for Promoter Activity Situated into the Exon 1 of This Gene and Provides Data about the Origin of the Nonmethylated State of These Types of Islands. Biochemical and Biophysical Research Communications, 1999, 254, 315-318.	2.1	14
130	An Isoform of Ataxinâ€3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients. Brain Pathology, 1998, 8, 669-679.	4.1	189
131	The ubiquitin pathway in Parkinson's disease. Nature, 1998, 395, 451-452.	27.8	1,518
132	His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. European Journal of Human Genetics, 1998, 6, 616-623.	2.8	56
133	Quality Assessment of Whole Genome Mapping Data in the Refined Familial Spastic Paraplegia Interval on Chromosome 14q. Genome Research, 1998, 8, 1216-1227.	5.5	22
134	SCA2 trinucleotide expansion in German SCA patients. Neurogenetics, 1997, 1, 59-64.	1.4	98
135	Fine scale mapping places DLG1, the gene encoding hDlg, telomeric to the OPA1 candidate region. Mammalian Genome, 1997, 8, 795-796.	2.2	3
136	Frequency of familial inheritance among 488 index patients with idiopathic focal dystonia and clinical variability in a large family. Movement Disorders, 1997, 12, 1000-1006.	3.9	81
137	Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature Genetics, 1996, 14, 269-276.	21.4	1,092
138	Molecular heterogeneity of autosomal dominant cerebellar ataxia: analysis of flanking microsatellites of the spinocerebellar ataxia 1 locus in a northern European family unequivocally demonstrates non-linkage. Human Genetics, 1993, 91, 362-6.	3.8	2
139	Machado-Joseph Disease Is Genetically Different from Holguin Dominant Ataxia (SCA2). Genomics, 1993, 17, 556-559.	2.9	4
140	Search for the Chromosomal Location of Autosomal Dominant Cerebellar Ataxia from Holguin, Cuba: Exclusion from Candidate Regions on Chromosome 4 and 11q. Human Heredity, 1993, 43, 12-20.	0.8	3
141	Developmental changes of nerve growth factor and its mRNA in the rat hippocampus: Comparison with choline acetyltransferase. Developmental Biology, 1987, 120, 322-328.	2.0	159
142	Spinocerebellar Ataxia Type 2. , 0, , .		3